In vivo effect of flucloxacillin in experimental endocarditis caused by mecC-positive staphylococcus aureus showing temperature-dependent susceptibility in vitro

Antimicrob Agents Chemother. 2015 Apr;59(4):2435-8. doi: 10.1128/AAC.04733-14. Epub 2015 Jan 20.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) carrying the mecC gene (mecC-MRSA) exhibited at 37°C MICs of oxacillin close to those of methicillin-susceptible S. aureus (MSSA). We investigated whether at this temperature, mecC-MRSA strains respond to flucloxacillin treatment like MSSA strains, using a rat model of endocarditis. Flucloxacillin (human-like kinetics of 2 g intravenously every 6 h) cured 80 to 100% of aortic vegetations infected with five different mecC-MRSA strains. These results suggest that mecC-MRSA infections may successfully respond to treatment with β-lactams.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Aorta / microbiology
  • Cefoxitin / pharmacology
  • Chromatography, Micellar Electrokinetic Capillary
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Floxacillin / administration & dosage
  • Floxacillin / therapeutic use*
  • Infusion Pumps
  • Methicillin-Resistant Staphylococcus aureus / genetics*
  • Microbial Sensitivity Tests
  • Oxacillin / pharmacology
  • Rats
  • Staphylococcal Infections / drug therapy*
  • Staphylococcal Infections / microbiology
  • Temperature

Substances

  • Anti-Bacterial Agents
  • Floxacillin
  • Cefoxitin
  • Oxacillin